RINVOQ 30 mg prolonged-release tablets

DRUG2 trials

Sponsors

Medical University Of Vienna, Centre Hospitalier Universitaire De Nice

Conditions

Antisynthetase SyndromDermatomyositisImmune-mediating necrotising myopathieLichenPolymyositisoverlap Myositis

Phase 2

A randomized, double-blind, placebo-controlled Phase II proof of concept study evaluating efficacy and safety of Upadacitinib in patients with idiopathic inflammatory myopathies after withdrawal of intravenous immunoglobulins (IVIG) (IVIG-Spare)

RecruitingCTIS2024-513681-19-00

Medical University Of ViennaAntisynthetase Syndrom, Dermatomyositis, Immune-mediating necrotising myopathie +2

Start: 2025-01-23Target: 10Updated: 2024-10-30

Upadacitinib in adult patients with erosive mucosal Lichen Planus and Lichen Planopilaris: a prospective multicenter randomized placebo-controlled study. (Upa30-LP)

Not yet recruitingCTIS2025-522870-35-00

Centre Hospitalier Universitaire De NiceLichen

Target: 56Updated: 2026-03-09